4MO Prognostic implication of 21-gene expression assay in luminal B type hormone receptor-positive breast cancer patients younger than 40 years

J Hyung,S Lee,J Kim,H.J Kim,B Ko,B-H Son,J Lee,H.J Lee,G Gong,H Lee,H Jeong,J-H Jeong,J.E Kim,J-H Ahn,K.H Jung,S-B Kim

doi:10.1016/j.annonc.2022.10.011

4MO Prognostic implication of 21-gene expression assay in luminal B type hormone receptor-positive breast cancer patients younger than 40 years

J Hyung, S Lee + Show 14 more

Open Access

https://doi.org/10.1016/j.annonc.2022.10.011

Copy DOI

Journal: Annals of Oncology	Publication Date: Nov 1, 2022
License type: publisher-specific-oa

Affiliation: Asan Medical Center

#Hormone Receptor-positive Breast Cancer Patients #Potential Benefits Of Adjuvant Chemotherapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Recurrence score (RS) based on 21-gene expression assay is widely used to evaluate prognosis and potential benefits of adjuvant chemotherapy (AC) for hormone-receptor positive (HR+) breast cancer (BC) patients (pts). In this study, we investigated clinical significance of RS in premenopausal HR+ BC pts.

Full Text